UNSPSC 51422348: Fluperolone acetate

This classification denotes a fluprednisolone analog C24H31FO6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier DOL7Q9DPF9, chemically known as androsta-1,4-dien-3-one, 17-(2-(acetyloxy)-1-oxopropyl)-9-fluoro-11,17-dihydroxy-, (11.beta.,17.alpha.,17(s))-, but more generally known as fluperolone acetate, which bears US NIH Compound Identifier 66257. Most nations, for tariff and trade purposes, schedule fluperolone acetate under HS 29372200 and SITC 54153.

As of Q4 2014, FLUPEROLONE ACETATE remains US FDA's Preferred Term for this commodity. SMILES: C[C@@H](C(=O)[C@]1(CC[C@@H]2[C@@]1(C[C@@H]([C@]3([C@H]2CCC4=CC(=O)C=C[C@@]43C)F)O)C)O)OC(=O)C.

UNSPSC 51422348 Fluperolone acetate is a Commodity code, but the recent state and local solicitations tagged under it do not match the product itself—the opportunities name naloxone, safe drug deactivation systems, and pharmacy benefit programs rather than fluperolone acetate, a corticosteroid medication. The mismatch signals a classification error in the source records, not genuine procurement activity under this code. State and local governments show little relevant recent activity for fluperolone acetate as a standalone procurement line item.

The two tagged opportunities—Seminole County, Florida's IFB for naloxone and drug deactivation systems (due July 26, 2023) and the Texas Health and Human Services Commission's RFI on direct-to-manufacturer prescription programs (April 3, 2026)—address opioid-crisis response and pharmacy benefit management, not corticosteroid supply. Without evidence of actual state or local solicitations for fluperolone acetate itself, this code does not support a pursue assessment at this time.